Synthetic biology company created as a joint venture between Bayer and Ginkgo Bioworks, focused on genetically engineering naturally occurring microbes to improve farmers’ crop yields, crop quality, and cost structure.
Joyn’s assets were acquired by Ginkgo in 2022 in exchange for rights to receive commercialization royalty payments.